Bleichroeder’s DiaMedica Therapeutics DMAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.16M Hold
382,317
– – 0.31% 57
2026
Q2
$2.69M Hold
382,317
– – 0.48% 30
2026
Q1
$2.59M Hold
382,317
– – 0.45% 29
2025
Q4
$3.04M Hold
382,317
– – 0.54% 23
2025
Q3
$2.63M Hold
382,317
– – 0.51% 25
2025
Q2
$1.49M Hold
382,317
– – 0.37% 25
2025
Q1
$1.45M Hold
382,317
– – 0.39% 24
2024
Q4
$2.08M Hold
382,317
– – 0.52% 20
2024
Q3
$1.6M Hold
382,317
– – 0.43% 25
2024
Q2
$1.13M Buy
382,317
+160,000
+72% +$439K 0.34% 29
2024
Q1
$616K Hold
222,317
– – 0.15% 37
2023
Q4
$631K Hold
222,317
– – 0.14% 33
2023
Q3
$574K Sell
222,317
-71,800
-24% -$231K 0.14% 30
2023
Q2
$1.27M Buy
+294,117
New +$714K 0.26% 32

Other funds holding DMAC

Bleichroeder's DMAC Position: Q3 2026 in Review

Bleichroeder held its DiaMedica Therapeutics (DMAC) position steady in Q3 2026 at 382,317 shares worth $3.16M. The position accounts for 0.31% of the portfolio, ranked #57.

Bleichroeder first reported a position in DMAC in Q2 2023 and has held it in 14 quarters since. 67 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

  • Bleichroeder held 382,317 shares of DiaMedica Therapeutics worth $3.16M as of Q3 2026.
  • Bleichroeder left its DiaMedica Therapeutics share count unchanged in Q3 2026.
  • DiaMedica Therapeutics made up 0.31% of Bleichroeder's portfolio in Q3 2026, its #57 holding.
  • Bleichroeder first reported a position in DiaMedica Therapeutics in Q2 2023 and has held it in 14 quarters since.
  • 67 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on Bleichroeder's 13F filing for Q3 2026, filed 13 Nov 2026.